Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07833436 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever

Study acronym: FIRST-IN-MOP
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Sep 15, 2026 to Sep 28, 2026
    • Site details revised
  2. Secondary endpoints revised (4)
    • Study title shortened, about 2 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Lassa fever is an acute viral disease belonging to the category of viral hemorrhagic fevers. It is endemic in West Africa. Outbreaks occur every year, and it is estimated that between 100 000 and 300 000 individuals are infected each year, with a fatality rate for symptomatic cases that ranges between 15 and 30%. There is no efficient treatment against the disease, as ribavirin, the only licensed therapy, is at best poorly efficient. MOPEVAC-Las is a live-attenuated vaccine candidate targeting Lassa virus. The objective of this phase 1 clinical trial is to evaluate the safety of the MOPEVAC-Las vaccine candidate on healthy volunteers. It will also evaluate the immunogenicity and optimal dose of the vaccine candidate. The main questions it aims to answer are: * What are the safety and tolerability of the MOPEVAC-Las vaccine candidate following two intramuscular injections in healthy volunteers ? * Are cell-mediated immunity and humoral immunity induced by the MOPEVAC-Las vaccine ? * What is the optimal dose of MOPEVAC-Las vaccine regarding safety, tolerability and immunogenicity ? Researchers will compare the MOPEVAC-Las vaccine candidate to a placebo (a look-alike substance that contains no drug).
Trial Details
NCT Number NCT07833436
Lead Sponsor Institut Pasteur
Conditions
(from sponsor)		 Lassa Fever
Related terms Lassa Fever
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov